|
1
|
El Serag HB: Hepatocellular carcinoma:
recent trends in the United States. Gastroenterology 127 (5 Suppl
1). 27–34. 2004.
|
|
2
|
Bosetti C, Levi F, Boffetta P, Lucchini F,
Negri E and La Vecchia C: Trends in mortality from hepatocellular
carcinoma in Europe, 1980–2004. Hepatology. 48:137–145. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaibori M, Ishizaki M, Matsui K and Kwon
AH: Predictors of microvascular invasion before hepatectomy for
hepatocellular carcinoma. J Surg Oncol. 102:462–468. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Funaki NO, Tanaka J, Seto SI, Kasamatsu T,
Kaido T and Imamura M: Hematogenous spreading of hepatocellular
carcinoma cells: Possible participation in recurrence in the liver.
Hepatology. 25:564–568. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruix J, Sherman M, Llovet JM, et al:
Clinical management of hepatocellular carcinoma. Conclusions of the
Barcelona-2000 EASL conference. European association for the study
of the liver. J Hepatol. 35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takayama T, Sekine T, Makuuchi M, et al:
Adoptive immunotherapy to lower postsurgical recurrence rates of
hepatocellular carcinoma: A randomised trial. Lancet. 356:802–807.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hui D, Qiang L, Jian W, Ti Z and Da-Lu K:
A randomized, controlled trial of postoperative adjuvant
cytokine-induced killer cells immunotherapy after radical resection
of hepatocellular carcinoma. Dig Liver Dis. 41:36–41. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weng DS, Zhou J, Zhou QM, et al: Minimally
invasive treatment combined with cytokine-induced killer cells
therapy lower the short-term recurrence rates of hepatocellular
carcinomas. J Immunother. 31:63–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou WP, Wu MC and Chen H: The effects of
combined hepatectomy and immuno-chemotherapy on postoperative
recurrence rate of primary liver cancer. Zhong Hua Wai Ke Za Zhi.
33:35–37. 1995.(In Chinese).
|
|
10
|
Zhong JH, Ma L, Wu LC, et al: Adoptive
immunotherapy for postoperative hepatocellular carcinoma: A
systematic review. Int J Clin Pract. 66:21–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma H, Zhang Y, Wang Q, et al: Therapeutic
safety and effects of adjuvant autologous RetroNectin activated
killer cell immunotherapy for patients with primary hepatocellular
carcinoma after radiofrequency ablation. Cancer Biol Ther.
9:903–907. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou P, Liang P, Dong B, Yu X, Han Z and
Xu Y: Phase clinical study of combination therapy with microwave
ablation and cellular immunotherapy in hepatocellular carcinoma.
Cancer Biol Ther. 11:450–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Ye L, Zhang J, Lin M, He S, Mao
X, Zhou X and Zhi F: MELD scores and Child-Pugh classifications
predict the outcomes of ERCP in cirrhotic patients with
choledocholithiasis: A retrospective cohort study. Medicine
(Baltimore). 94:e4332015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu SR, Liang P, Yu XL, Cheng ZG, Han ZY
and Yu J: Percutaneous microwave ablation for liver tumours
adjacent to the marginal angle. Int J Hyperthermia. 30:306–311.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Usuda S, Yoshizawa K, Yabu K and Kiyosawa
K: Immunological responses against an autologous human
hepatocellular carcinoma cell line. J Gastroenterol Hepatol.
8:517–523. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong L, Yao SK, Liu JX and Wang N: The
prognostic value of cellular immunity function in patients with
hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi.
13:194–197. 2005.PubMed/NCBI
|
|
17
|
Deguchi Y, Yoshimatsu K and Endo S:
Natural killer-like T cell lymphoma of the small intestine: Report
of a case. Surg Today. 36:474–477. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu HR and Li WM: Treg-specific
demethylated region activity in isolated regulatory t lymphocytes
is a surrogate for disease severity in hepatocellular carcinoma.
IUBMB Life. 67:355–360. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Passalacqua G, BaenaCagnani CE, Bousquet
J, Canonica GW, Casale TB, Cox L, Durham SR, LarenasLinnemann D,
Ledford D, Pawankar R, et al: Grading local side effects of
sublingual immunotherapy for respiratory allergy: Speaking the same
language. J Allergy Clin Immunol. 132:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cox L, LarenasLinnemann D, Lockey RF and
Passalacqua G: Speaking the same language: The World Allergy
Organization subcutaneous immunotherapy systemic reaction grading
system. J Allergy Clin Immunol. 25:569–574. 2010. View Article : Google Scholar
|
|
21
|
Song R, Ikeguchi M, Zhou G and Kuo MT:
Identification and characterization of a hepatoma cell-specific
enhancer in the mouse multidrug resistance mdr1b promoter. J Biol
Chem. 270:25468–25474. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen TM, Lin CC, Huang PT and Wen CF:
Neutrophil-to-lymphocyte ratio associated with mortality in early
hepatocellular carcinoma patients after radiofrequency ablation. J
Gastroenterol Hepatol. 27:553–561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koh YW, Kang HJ, Park C, et al: The ratio
of the absolute lymphocyte count to the absolute monocyte count is
associated with prognosis in Hodgkin's lymphoma: correlation with
tumor-associated macrophages. Oncologist. 17:871–880. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee CS: Lymphocytes and their subsets in
the peripheral blood of hepatocellular carcinoma patients. J Formos
Med Assoc. 90:626–630. 1991.PubMed/NCBI
|
|
25
|
Wang JX, Liu GH, Fan YZ, et al: Effects of
cytotoxic T lymphocytes on hepatoma cell line SMMC-7721 induced by
different subsets of dendritic cells in vitro. Hepatobiliary
Pancreat Dis Int. 5:422–427. 2006.PubMed/NCBI
|
|
26
|
Olioso P, Giancola R, Di Riti M, Contento
A, Accorsi P and Iacone A: Immunotherapy with cytokine induced
killer cells in solid and hematopoietic tumours: A pilot clinical
trial. Hematol Oncol. 27:130–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu YR, Yang CL, Chen LB and Wang Q:
Analysis of CD8 (+) and CD8 (+) CD28 (-) cell subsets in patients
with hepatocellular carcinoma. Di Yi Jun Yi Da Xue Xue Bao.
22:72–73. 2002.(In Chinese). PubMed/NCBI
|
|
28
|
Shibolet O, Alper R, Zlotogarov L, et al:
Suppression of hepatocellular carcinoma growth via oral immune
regulation towards tumor-associated antigens is associated with
increased NKT and CD8+lymphocytes. Oncology. 66:323–330.
2004. View Article : Google Scholar : PubMed/NCBI
|
